iBio (IBIO) Share-based Compensation (2010 - 2026)
iBio (IBIO) posted quarterly Share-based Compensation of $377000.0 for Q1 2026, up 1.89% year-over-year from $370000.0 in Q1 2025, and up 49.01% quarter-over-quarter from $253000.0 in Q4 2025.
iBio (IBIO) Share-based Compensation (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Share-based Compensation for 17 consecutive years, with $377000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 1.89% year-over-year to $377000.0; the TTM figure through Mar 2026 stood at $1.2 million (down 24.88% YoY), while the FY2025 annual figure was $2.7 million, up 30.42% from the prior year.
- Share-based Compensation advanced to $377000.0 in Q1 2026 per IBIO's latest filing, from $253000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.2 million in Q1 2022 and bottomed at -$1.1 million in Q2 2023.
- Historically, Share-based Compensation has averaged $465941.2 across 5 years, with a median of $454000.0 in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 224.33% — and 2023, when it tumbled 242.37%.
- iBio's Share-based Compensation stood at $915000.0 in 2022, then sank by 50.38% to $454000.0 in 2023, then gained by 4.63% to $475000.0 in 2024, then sank by 46.74% to $253000.0 in 2025, then surged by 49.01% to $377000.0 in 2026.
- Business Quant data shows IBIO's Share-based Compensation at $377000.0 in Q1 2026, $253000.0 in Q4 2025, and $323000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | iBio | 175.21 Mn | 175.21 Mn | - | 377,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 377,000.00 |
| Mar 31, 2026 | 377,000.00 |
| Dec 31, 2025 | 253,000.00 |
| Dec 31, 2025 | 253,000.00 |
| Sep 30, 2025 | 323,000.00 |
| Sep 30, 2025 | 323,000.00 |
| Jun 30, 2025 | 270,000.00 |
| Jun 30, 2025 | 270,000.00 |
| Mar 31, 2025 | 370,000.00 |
| Mar 31, 2025 | 370,000.00 |
| Dec 31, 2024 | 475,000.00 |
| Dec 31, 2024 | 475,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Jun 30, 2024 | 368,000.00 |
| Jun 30, 2024 | 368,000.00 |
| Mar 31, 2024 | 454,000.00 |
| Mar 31, 2024 | 454,000.00 |
| Dec 31, 2023 | 454,000.00 |
| Dec 31, 2023 | 454,000.00 |